Welcome!

News Feed Item

/C O R R E C T I O N -- BioMed Realty/

In the news release, BioMed Realty Invests In Life Science Research Facilities Leased To Yale University, Yale-New Haven Hospital And Alexion Pharmaceuticals, issued 07-Apr-2014 by BioMed Realty over PR Newswire, we are advised by the company that the 4th paragraph, 1st sentence, should read "...a global pharmaceutical company with a marketed product, Soliris®..." rather than, "...a global pharmaceutical company with a marketed product, Solaris®..." as originally issued inadvertently. The complete, corrected release follows:

BioMed Realty Invests In Life Science Research Facilities Leased To Yale University, Yale-New Haven Hospital And Alexion Pharmaceuticals

Two properties will aggregate over 1.0 million square feet upon completion

SAN DIEGO, April 7, 2014 /PRNewswire/ -- BioMed Realty Trust, Inc. (NYSE: BMR) today announced the investment in two properties, 300 George Street and 100 College Street, in the growing life science research community adjacent to the Yale School of Medicine in New Haven, Connecticut. 

BioMed Realty Trust Logo. (PRNewsFoto/BioMed Realty Trust)

The property at 300 George Street is a nine-story, 519,000 square foot laboratory and office building, which is anchored by long term leases to Yale University and the Yale-New Haven Hospital.  The second building at 100 College Street, currently under construction, will be a 14-story, fully leased 508,000 square foot laboratory and office project anchored by Alexion Pharmaceuticals, Inc.  Alexion was founded in New Haven in 1992, and will use the 100 College building as its new global headquarters. 

The total project investment, upon completion, is expected to be approximately $308 million including a continuing partnership interest of Winstanley Enterprises LLC, which will also continue to provide construction and property management services for the project. 

"This opportunity allows BioMed Realty and Wexford to work with and build upon the established relationships with world-renowned tenants like Yale University, Yale-New Haven Hospital and Alexion, a global pharmaceutical company with a marketed product, Soliris®, and a robust research pipeline," said Kent Griffin, President of BioMed Realty.  "We look forward to utilizing our expertise in the well-established life science community in New Haven."

"This is an exciting day for Winstanley Enterprises as we join with BioMed Realty and Wexford to continue the successful partnerships we have established with the City of New Haven, Yale University, and the local life sciences community," observed Carter Winstanley, Principal with Winstanley Enterprises. "We believe this venture will provide vibrant real estate solutions to facilitate continued innovation between public and private industry for many years to come."

"We are excited about this opportunity to expand our university-anchored, knowledge community platform – particularly with this high quality project supporting Yale University, Yale-New Haven Hospital and Alexion Pharmaceuticals," said James Berens, President of Wexford Science & Technology.  "We look forward to working closely with Carter Winstanley and his talented team supporting the increasingly vibrant New Haven market. Given the strong foundations which the local community and Yale University have created in concert with our partner, Winstanley Enterprises, we see New Haven as a center of excellence which will drive collaboration with top tier researchers from around the world."

Additional information regarding the investment is available under the Investor Relations section of BioMed Realty's website at http://phx.corporate-ir.net/phoenix.zhtml?c=182385&p=irol-IRHome.

About BioMed Realty Trust

BioMed Realty, with its trusted expertise and valuable relationships, delivers optimal real estate solutions for biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed Realty owns or has interests in properties comprising approximately 17.3 million rentable square feet.  Additional information is available at www.biomedrealty.com. Follow us on Twitter @biomedrealty.

About Wexford Science & Technology

Wexford Science & Technology, a subsidiary of BioMed Realty, is a real estate investment and development company specializing in facilities for for-profit and not-for-profit institutions, especially universities, university-related research parks and healthcare systems.  Wexford brings a unique approach of collaborating with clients to build knowledge communities which are vibrant, mixed-use, amenity-rich environments that foster innovation. 

About Winstanley Enterprises

Winstanley Enterprises LLC, based in Concord, Massachusetts, invests in and develops commercial real estate assets. Operating primarily in the Northeast United States, Winstanley invests across all commercial asset classes with a particular expertise in the laboratory and life sciences industry.  Winstanley provides a wide range of integrated development, tenant and investor services through its corporate staff and operating subsidiaries, Winstanley Property Management LLC and Winstanley Construction Management LLC.  Additional information is available at http://www.winent.com/.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties include, without limitation: failure to manage effectively BioMed Realty Trust, Inc.'s (the "company") growth and expansion into new markets, or to complete or integrate acquisitions and developments successfully, including the investments in 300 George Street and 100 College Street in New Haven, Connecticut; risks and uncertainties affecting property development and construction, including completion of construction of the 100 College Street property: general risks affecting the real estate industry (including, without limitation, the inability to enter into or renew leases, dependence on tenants' financial condition, and competition from other developers, owners and operators of real estate); adverse economic or real estate developments in the life science industry or the company's target markets; risks associated with the availability and terms of financing, the use of debt to fund acquisitions, developments and other investments, and the ability to refinance indebtedness as it comes due; failure to maintain the company's investment grade credit ratings with the ratings agencies; failure to manage effectively the company's growth and expansion into new markets, or to complete or integrate acquisitions and developments successfully; reductions in asset valuations and related impairment charges; risks and uncertainties affecting property development and construction; risks associated with tax credits, grants and other subsidies to fund development activities; risks associated with downturns in foreign, domestic and local economies, changes in interest rates and foreign currency exchange rates, and volatility in the securities markets; ownership of properties outside of the United States that subject the company to different and potentially greater risks than those associated with the company's domestic operations; risks associated with the company's investments in loans, including borrower defaults and potential principal losses; potential liability for uninsured losses and environmental contamination; risks associated with the company's potential failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended, and possible adverse changes in tax and environmental laws; and risks associated with the company's dependence on key personnel whose continued service is not guaranteed. For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission, including the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. 

Logo - http://photos.prnewswire.com/prnh/20091005/BIOMEDLOGO

 

SOURCE BioMed Realty

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
NHK, Japan Broadcasting, will feature the upcoming @ThingsExpo Silicon Valley in a special 'Internet of Things' and smart technology documentary that will be filmed on the expo floor between November 3 to 5, 2015, in Santa Clara. NHK is the sole public TV network in Japan equivalent to the BBC in the UK and the largest in Asia with many award-winning science and technology programs. Japanese TV is producing a documentary about IoT and Smart technology and will be covering @ThingsExpo Silicon Val...
The 20th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held June 6-8, 2017, at the Javits Center in New York City, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Containers, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportunity. Submit your speaking proposal ...
SYS-CON Events announced today that CollabNet, a global leader in enterprise software development, release automation and DevOps solutions, will be a Bronze Sponsor of SYS-CON's 20th International Cloud Expo®, taking place from June 6-8, 2017, at the Javits Center in New York City, NY. CollabNet offers a broad range of solutions with the mission of helping modern organizations deliver quality software at speed. The company’s latest innovation, the DevOps Lifecycle Manager (DLM), supports Value S...
Building a cross-cloud operational model can be a daunting task. Per-cloud silos are not the answer, but neither is a fully generic abstraction plane that strips out capabilities unique to a particular provider. In his session at 20th Cloud Expo, Chris Wolf, VP & Chief Technology Officer, Global Field & Industry at VMware, will discuss how successful organizations approach cloud operations and management, with insights into where operations should be centralized and when it’s best to decentraliz...
The age of Digital Disruption is evolving into the next era – Digital Cohesion, an age in which applications securely self-assemble and deliver predictive services that continuously adapt to user behavior. Information from devices, sensors and applications around us will drive services seamlessly across mobile and fixed devices/infrastructure. This evolution is happening now in software defined services and secure networking. Four key drivers – Performance, Economics, Interoperability and Trust ...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm. In his Day 3 Keynote at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, will explore t...
With billions of sensors deployed worldwide, the amount of machine-generated data will soon exceed what our networks can handle. But consumers and businesses will expect seamless experiences and real-time responsiveness. What does this mean for IoT devices and the infrastructure that supports them? More of the data will need to be handled at - or closer to - the devices themselves.
@DevOpsSummit at Cloud taking place June 6-8, 2017, at Javits Center, New York City, is co-located with the 20th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long developm...
Cloud Expo, Inc. has announced today that Aruna Ravichandran, vice president of DevOps Product and Solutions Marketing at CA Technologies, has been named co-conference chair of DevOps at Cloud Expo 2017. The @DevOpsSummit at Cloud Expo New York will take place on June 6-8, 2017, at the Javits Center in New York City, New York, and @DevOpsSummit at Cloud Expo Silicon Valley will take place Oct. 31-Nov. 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo 2016 in New York. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Internet of @ThingsExpo, taking place June 6-8, 2017, at the Javits Center in New York City, New York, is co-located with 20th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry p...
Translating agile methodology into real-world best practices within the modern software factory has driven widespread DevOps adoption, yet much work remains to expand workflows and tooling across the enterprise. As models evolve from pockets of experimentation into wholescale organizational reinvention, practitioners find themselves challenged to incorporate the culture and architecture necessary to support DevOps at scale. In his session at @DevOpsSummit at 20th Cloud Expo, Anand Akela, Senior...
Join IBM November 2 at 19th Cloud Expo at the Santa Clara Convention Center in Santa Clara, CA, and learn how to go beyond multi-speed it to bring agility to traditional enterprise applications. Technology innovation is the driving force behind modern business and enterprises must respond by increasing the speed and efficiency of software delivery. The challenge is that existing enterprise applications are expensive to develop and difficult to modernize. This often results in what Gartner calls ...
In his keynote at @ThingsExpo, Chris Matthieu, Director of IoT Engineering at Citrix and co-founder and CTO of Octoblu, focused on building an IoT platform and company. He provided a behind-the-scenes look at Octoblu’s platform, business, and pivots along the way (including the Citrix acquisition of Octoblu).
Grape Up is a software company, specialized in cloud native application development and professional services related to Cloud Foundry PaaS. With five expert teams that operate in various sectors of the market across the USA and Europe, we work with a variety of customers from emerging startups to Fortune 1000 companies.
Financial Technology has become a topic of intense interest throughout the cloud developer and enterprise IT communities. Accordingly, attendees at the upcoming 20th Cloud Expo at the Javits Center in New York, June 6-8, 2017, will find fresh new content in a new track called FinTech.